Amneal Pharmaceuticals, Inc. AMRX
At closeNov 5, 2026, 4:00 PM EST
After hours · Nov 5, 4:00 PM ET
- YTD
- +54.37%
- 1 year
- +66.38%
- Market cap
- 6.77B
- Revenue (ttm)
- 3.20B
- Profit margin
- 4.17%
- EPS (ttm)
- 0.40
- Shares out
- 348.30M
- P/E ratio
- 48.63
- Forward P/E
- 16.03
- YTD return
- +54.37%
- 1-year return
- +66.38%
- Volume
- 3.41M
- Avg volume
- 3.08M
- Open
- 20.04
- Previous close
- 19.95
- Day's range
- 19.39 – 20.48
- 52-week range
- 11.30 – 21.68
- Beta
- 1.21
- Analysts
- Strong Buy
- Price target
- 23.43 (+20.5%)
- Earnings date
- Feb 26, 2027
5D -2.13 (-9.87%)
Key statistics
- Enterprise value
- 9.93B
- PEG ratio
- 1.92
- Price / sales
- 2.12
- Price / book
- 12.29
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 10.00%
- Free cash flow
- -42.07M
- Total cash
- 157.40M
- Total debt
- 3.28B
- Return on equity
- 70.00%
- Short % of float
- 5.74%
- 50-day average
- 19.26
- 200-day average
- 15.85
Analyst view
Consensus: strong buy
- Target (low)
- 20.00
- Target (mean)
- 23.43
- Target (high)
- 27.00
- Strong buy3
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 26, 2027
Expected Feb 26, 2027. Consensus EPS estimate 0.22003.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 26, 2027 | Dec 30, 2026 | 0.24 | — | — | — |
| Nov 3, 2026 | Sep 30, 2026 | 0.2374 | 0.26 | +0.02 | +9.52% |
| Jul 30, 2026 | Jun 30, 2026 | 0.2225 | 0.30 | +0.08 | +34.83% |
| May 7, 2026 | Mar 31, 2026 | 0.17 | 0.27 | +0.10 | +58.82% |
| Feb 27, 2026 | Dec 31, 2025 | 0.18 | 0.21 | +0.03 | +16.67% |
| Oct 30, 2025 | Sep 30, 2025 | 0.13 | 0.17 | +0.04 | +30.77% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 4, 2026 | JP Morgan | main | Overweight | Overweight |
| Oct 22, 2026 | JP Morgan | main | Overweight | Overweight |
| Sep 23, 2026 | Oppenheimer | init | — | Outperform |
| Sep 17, 2026 | Barclays | main | Overweight | Overweight |
| Sep 9, 2026 | Leerink Partners | init | — | Outperform |
| Aug 3, 2026 | UBS | main | Buy | Buy |
About Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- amneal.com
News
Leerink Partners Maintains Outperform on Amneal Pharmaceuticals, Raises Price Target to $25 
JP Morgan Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $25 
AMRX Q3 Earnings & Sales Beat Estimates, FY'26 Guidance Raised 
Amneal Pharmaceuticals, Inc. (AMRX) Q3 2026 Earnings Call Transcript 
What Amneal Pharmaceuticals (AMRX) Said on Its Q3 Earnings Call 
Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say 
Amneal Pharmaceuticals Q3 2026 Earnings Call Transcript 
Amneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Top Estimates 
Amneal Pharmaceuticals Raises FY2026 Adj EPS Guidance from $0.96-$1.06 to $1.04-$1.08 vs $1.03 Est; Raises FY2026 Sales Guidance from $3.100B-$3.200B to $3.150B-$3.250B vs $3.159B Est 
Amneal Pharmaceuticals Q3 Adj. EPS $0.26 Beats $0.23 Estimate, Sales $862.684M Beat $816.058M Estimate
Your note
Sign in to keep a note on AMRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GEORGE JEFFREY P. | Director | Conversion of Exercise of derivative security | May 6, 2026 | 344,614 |
| KONIDARIS TASOS | Chief Financial Officer | Conversion of Exercise of derivative security | Mar 3, 2026 | 449,434 |
| MEISTER PAUL M | Director | Conversion of Exercise of derivative security | May 6, 2026 | 832,800 |
| NARK THEODORE C. | Director | Conversion of Exercise of derivative security | May 6, 2026 | 325,848 |
| PATEL CHINTU | Chief Executive Officer | Stock Award(Grant) | Aug 9, 2026 | 0 |
| PATEL CHIRAG K | Chief Executive Officer | Stock Award(Grant) | Aug 9, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.67% | 26,562,093 | 516.63M | Jun 29, 2026 |
| TPG GP A, LLC | 4.02% | 12,328,767 | 239.79M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 3.96% | 12,137,727 | 236.08M | Jun 29, 2026 |
| Rubric Capital Management LP | 3.32% | 10,168,660 | 197.78M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 2.52% | 7,710,126 | 149.96M | Jun 29, 2026 |
| State Street Corporation | 2.40% | 7,356,977 | 143.09M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 3.59% | 10,992,537 | 213.80M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.81% | 5,555,668 | 108.06M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.31% | 4,029,125 | 78.37M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.31% | 4,020,772 | 78.20M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund | 0.83% | 2,549,077 | 49.58M | Jun 29, 2026 |
| Invesco Exchange-Traded Fund Trust-Invesco S&P SmallCap Momentum ETF | 0.68% | 2,084,528 | 40.54M | Sep 29, 2026 |